Skip to main content

Table 4 Summary of success rate following a single oral dose of Credelio Plus against natural nematode infections in dogs presenting to European veterinary clinics

From: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Nematode species Treatment groupa Number of dogs Success rateb Difference in success rate
Successful dogs Success rate (%) Estimate 95% Confidence intervalc
All nematode species Credelio Plus
Afoxolaner + MO
278
117
254
103
91.4
88.0
3.33
(− 3.41, 10.08)
T. canis Credelio Plus
Afoxolaner + MO
54
19
48
16
88.9
84.2
4.68
(− 13.74, 23.09)
A. caninum Credelio Plus
Afoxolaner + MO
109
42
103
38
94.5
90.5
4.02
(− 5.84, 13.88)
T. vulpis Credelio Plus
Afoxolaner + MO
176
80
161
75
91.5
93.8
− 2.27
(− 8.99, 4.45)
  1. MO milbemycin oxime
  2. aSingle oral administration of Credelio Plus on Day 0 to provide a dose range of 0.75–1.56 mg/kg bodyweight MO and 20.0–41.5 mg/kg bodyweight lotilaner. Single oral dose of Nexgard Spectra on Day 0 to provide a dose range of 2.50–5.36 mg/kg bodyweight of afoxolaner and 0.50–1.07 mg/kg bodyweight of MO
  3. bSuccessfully treated dog is one for whom the individual percentage reduction in egg counts at Day 8, relative to Day 0, is at least 90%
  4. cConfidence interval for the difference (Credelio Plus – Nexgard Spectra) in proportions of two independent samples. Non-inferiority is accepted when the lower limit of the interval is greater than − 15